ACE2016

Phase 1Small molecule

AAcepodia Biotech, Inc.

ACE2016 is one of 44 small molecule programs targeting Growth. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

GrowthRecruiting

GrowthPhase 1

Recruiting

Competition

Competitive Landscape

79 competitors in Growth

#DrugCompanyPhaseTrials

Growth Hormone

Pfizer

Phase 3

30 2

Neo-Synephrine

EExela Pharma Sciences, LLC.

Phase 3

1 3

Recombinant Human Growth Hormone

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

8 4

Piqray

Novartis

Phase 2

2 5

Acipimox

Boehringer Ingelheim

Phase 2

1 6

Lenvima

Eisai

Preclinical

1 7

Zolymbus

AbbVie

Preclinical

1 8

Aricept

Eisai

Preclinical

1 9

Zyloprim

Jazz Pharmaceuticals

Preclinical

1 10

Miransertib

Merck & Co.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Growth

NCT06415487

Clinical

Trials by Indication[1]

Growth1 trial

ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR)

Recruiting·AAcepodia Biotech, Inc.·Phase 1·NCT06415487·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ACE2016. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ACE2016 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ACE2016. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Acepodia Biotech, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAcepodia Biotech, Inc.

ACE2016

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Growth1 trial

References

Drug Info

Quick Facts

Related News